Bär & Karrer has acted as Swiss legal and tax advisor to Holcim and its North American Amrize in planning the latter’s spin-off, corporate governance set-up, and public listing process. The Amrize shares debuted both on the New York Stock Exchange and on the SIX Swiss Exchange (SIX). The company reached a market cap of […]
Homburger advised the Julius Baer Group on its issuance of EUR 500 m notes. The issuance The operation took place indirectly through the ELM issuance vehicle, a repackaging issuance entity incorporated in the Netherlands. The notes &
Homburger advised Raiffeisen Schweiz Genossenschaft in connection with its role as sole lead manager on EFG Bank’s issuance of CHF 125 m 0.9625% bonds, maturing in 2029. EFG Bank completed the issuance on June 18th. The Homburger
Homburger advised ADC Therapeutics on its USD 100 m Private Placement of Common Shares and Pre-Funded Warrants. The context Headquartered in Switzerland and listed on the NYSE under the ticker ADCT, ADC Therapeutics is a commercial-stage
Vischer advised Mosanna Therapeutics in connection with its USD 80m Series A funding round. Headquartered in Basel, Switzerland, the clinical-stage biotech company, is working on a nighttime nasal spray to treat obstructive sleep apnea (OSA).
Baker McKenzie Switzerland – along with Baker McKenzie lawyers from the UK, US, Germany and further European jurisdictions – advised DocMorris on its rights offering with gross proceeds of CHF 208 million. In connection with the deal, Advestra
Pestalozzi advises a group of financial institutions representing a majority of holders of CHF 800 million in aggregate of convertible bonds issued by Idorsia, in connection with the holistic restructuring of the company. The context Headquartered
Homburger advised SIX Group AG on the issuance of EUR 500 m guaranteed bonds and CHF 250 m digital bonds.The two issuances took place respectively on 30 May 2025 and 4 June 2025, the first consisting in 500 m guaranteed bonds
Niederer Kraft Frey (NKF) represented the banking syndicate and Homburger advised consortium leader EQT on the sale of 8.0% of Galderma’s share capital via an accelerated bookbuilding process. The operation On May 27, 2025, a consortium led
Vischer advised GlycoEra in connection with its financing round. The Swiss biotechnology company, closed a USD 130 million Series B funding. BGPartner advised the lead investor Novo Holdings and new investor LifeArc Ventures on all Swiss
